La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Marksans Pharma Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Mark Saldanha

Amministratore delegato

₹52.2m

Compenso totale

Percentuale dello stipendio del CEO	92.0%
Mandato del CEO	8.8yrs
Proprietà del CEO	43.8%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Jul 28

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Sep 16

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

Sep 01

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt

Jun 14

Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?

May 27

Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?

Feb 19

Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Feb 04

Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching

Jan 20

Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?

Jan 05

Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%

Dec 21

What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?

Dec 06

These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely

Nov 19

Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?

Nov 04

If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late

Oct 20

Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?

Oct 05

If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns

Sep 20

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mark Saldanha rispetto agli utili di Marksans Pharma?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	₹3b
Mar 31 2024	n/a	n/a	₹3b
Dec 31 2023	n/a	n/a	₹3b
Sep 30 2023	n/a	n/a	₹3b
Jun 30 2023	n/a	n/a	₹3b
Mar 31 2023	₹52m	₹48m	₹3b
Dec 31 2022	n/a	n/a	₹2b
Sep 30 2022	n/a	n/a	₹2b
Jun 30 2022	n/a	n/a	₹2b
Mar 31 2022	₹38m	₹35m	₹2b
Dec 31 2021	n/a	n/a	₹2b
Sep 30 2021	n/a	n/a	₹2b
Jun 30 2021	n/a	n/a	₹3b
Mar 31 2021	₹10m	₹10m	₹2b
Dec 31 2020	n/a	n/a	₹2b
Sep 30 2020	n/a	n/a	₹2b
Jun 30 2020	n/a	n/a	₹1b
Mar 31 2020	₹10m	₹10m	₹1b
Dec 31 2019	n/a	n/a	₹879m
Sep 30 2019	n/a	n/a	₹834m
Jun 30 2019	n/a	n/a	₹780m
Mar 31 2019	₹10m	₹10m	₹804m
Dec 31 2018	n/a	n/a	₹666m
Sep 30 2018	n/a	n/a	₹582m
Jun 30 2018	n/a	n/a	₹463m
Mar 31 2018	₹12m	₹10m	₹358m

Compensazione vs Mercato: La retribuzione totale di Mark ($USD 621.97K ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 384.17K ).

Compensazione vs guadagni: La retribuzione di Mark è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Mark Saldanha (52 yo)

8.8yrs

Mandato

₹52,161,600

Compensazione

Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Mark Saldanha	Non-Independent Executive Chairman & MD	8.8yrs	₹52.16m	43.8% ₹ 43.7b
Sandra Saldanha	Whole-time Director	9.9yrs	₹7.03m	0.073% ₹ 72.7m
Varddhman Jain	Whole-time Director	5.6yrs	₹15.25m	Nessun dato
Sunny Sharma	Non-Executive Director & Non-Independent	3yrs	Nessun dato	Nessun dato
Abhinna Mohanty	Non-Executive & Independent Director	5.1yrs	₹40.00k	Nessun dato
Shailaja Vardhan	Independent Director	1.3yrs	Nessun dato	Nessun dato
Seetharama Buddharaju	Non-Executive & Independent Director	12.8yrs	₹40.00k	Nessun dato
Digant Parikh	Non-Executive Independent Director	6.4yrs	₹200.00k	Nessun dato

6.0yrs

Durata media

53.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MARKSANS sono considerati esperti (durata media dell'incarico 6 anni).

Marksans Pharma Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Marksans Pharma Limited, Annual General Meeting, Sep 24, 2024

Whole-time Director recently bought ₹6.9m worth of stock

Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director

Marksans Pharma Limited, Annual General Meeting, Aug 28, 2023

Insufficient new directors

Marksans Pharma Limited, Annual General Meeting, Aug 29, 2022

Recent updates

Successful Closure of US FDA Inspection At Marksans Pharma's Manufacturing Facility Located At Verna, Goa

Investor sentiment improves as stock rises 17%

New minor risk - Share price stability

Marksans Pharma Limited, Annual General Meeting, Sep 24, 2024

First quarter 2025 earnings released: EPS: ₹1.96 (vs ₹1.52 in 1Q 2024)

Marksans Pharma Limited to Report Q1, 2025 Results on Aug 13, 2024

Now 20% overvalued after recent price rise

Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company

Investor sentiment improves as stock rises 18%

Whole-time Director recently bought ₹6.9m worth of stock

Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Full year 2024 earnings: EPS misses analyst expectations

Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?

Marksans Pharma Limited Recommends Final Dividend for the Financial Year 2023-24

Marksans Pharma Limited to Report Q4, 2024 Results on May 30, 2024

Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 23% overvalued after recent price rise

Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors

Marksans Pharma Limited to Report Q3, 2024 Results on Feb 13, 2024

We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: ₹1.84 (vs ₹1.52 in 2Q 2023)

Marksans Pharma Limited to Report Q2, 2024 Results on Nov 09, 2023

Marksans Pharma Limited Appoints Shailaja Vardhan as an Independent Director

Marksans Pharma Ltd. Receives USFDA Approval for Guaifenesin Extended-Release Tablets

Marksans Pharma Limited Recommends Payment of Dividend for the Financial Year 2022-23

Full year 2023 earnings released: EPS: ₹6.39 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited, Annual General Meeting, Aug 28, 2023

Insufficient new directors

Investor sentiment improves as stock rises 16%

Marksans Pharma Limited Announces That It Has Received Final Approval from the Us Food and Drug Administration for Its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 Mg/125 Mg

Marksans Pharma Limited Approves Declaration of Dividend for the Financial Year 2022-23, Payable on or After 12 June, 2023

Full year 2023 earnings released: EPS: ₹6.41 (vs ₹4.56 in FY 2022)

Marksans Pharma Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released: EPS: ₹1.56 (vs ₹1.20 in 3Q 2022)

Marksans Pharma Limited to Report Q3, 2023 Results on Feb 13, 2023

Marksans Pharma Limited announced that it has received funding from OrbiMed Asia IV Mauritius FVCI Limited

Second quarter 2023 earnings released: EPS: ₹1.52 (vs ₹1.11 in 2Q 2022)

Marksans Pharma Limited to Report Q2, 2023 Results on Nov 14, 2022

Marksans Pharma Limited (BSE:524404) entered into a Business Transfer Agreement to acquire Bulk Pharmaceutical Business of Tevapharm India Private Limited.

Marksans Pharma Limited Declares Dividend, Payable on or After 20 September 2022

Upcoming dividend of ₹0.25 per share

Full year 2022 earnings released: EPS: ₹4.56 (vs ₹5.83 in FY 2021)

Marksans Pharma Limited to Report Q1, 2023 Results on Aug 13, 2022

Marksans Pharma Limited, Annual General Meeting, Aug 29, 2022

Marksans Pharma Limited Announces US FDA Approval for Pregabalin Capsules

Marksans Pharma Limited (BSE:524404) announces an Equity Buyback for INR 600 million worth of its shares.

Investor sentiment improved over the past week

Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly

Marksans Pharma Limited (BSE:524404) completed the acquisition of Access Healthcare for Medical Products LLC.

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Marksans Pharma Recommends Final Dividend for the Financial Year Ended 31st March, 2022

Full year 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Fiscal Year 2022 Results on May 30, 2022

Marksans Pharma Limited (BSE:524404) has signed agreement to acquire share capital of Access Healthcare for Medical Products LLC for AED 13 million.

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Marksans Pharma Limited to Report Q3, 2022 Results on Feb 11, 2022

Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)

Second quarter 2022 earnings released: EPS ₹1.11 (vs ₹1.21 in 2Q 2021)

This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation

Upcoming dividend of ₹0.25 per share

Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25

First quarter 2022 earnings released: EPS ₹1.51 (vs ₹1.20 in 1Q 2021)

Investor sentiment deteriorated over the past week

Marksans Pharma Limited announced that it has received INR 930.999994 million in funding from OrbiMed Asia IV Mauritius FVCI Limited and other investor

Marksans Pharma Limited announced that it expects to receive INR 930.999994 million in funding

Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt